Acurx Pharmaceuticals Inc. (ACXP): רווח נקי למניה (EPS TTM)

The development of antibiotics for intensive care units provides Acurx Pharmaceuticals (ACXP) with stable hospital demand, establishing a strong brand reputation among physicians. The TTM net income per share confirms this trend, with the current value standing at -2.33. The picture is completed by prolonged clinical trials and the fight against resistance, which require constant investment in R&D to protect patents.

Acurx Pharmaceuticals focuses on developing innovative antibiotics to combat resistant pathogens. This indicator calculates the aggregate net income over a rolling year divided by the total number of shares. This metric allows for an assessment of the real return on each share of capital, eliminating distortions from one-time payments. Investors use this calculation to determine the fair value of the asset and analyze the risks of overpayment. The trend in fundamental earnings per share TTM reflects the financial efficiency of developing targeted drugs.